126 related articles for article (PubMed ID: 21936566)
21. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.
Pritchard AL; Hayward NK
Clin Cancer Res; 2013 May; 19(9):2301-9. PubMed ID: 23406774
[TBL] [Abstract][Full Text] [Related]
22. Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling.
Furlan A; Colombo F; Kover A; Issaly N; Tintori C; Angeli L; Leroux V; Letard S; Amat M; Asses Y; Maigret B; Dubreuil P; Botta M; Dono R; Bosch J; Piccolo O; Passarella D; Maina F
Eur J Med Chem; 2012 Jan; 47(1):239-54. PubMed ID: 22138308
[TBL] [Abstract][Full Text] [Related]
23. Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.
Smith BD; Kaufman MD; Leary CB; Turner BA; Wise SC; Ahn YM; Booth RJ; Caldwell TM; Ensinger CL; Hood MM; Lu WP; Patt TW; Patt WC; Rutkoski TJ; Samarakoon T; Telikepalli H; Vogeti L; Vogeti S; Yates KM; Chun L; Stewart LJ; Clare M; Flynn DL
Mol Cancer Ther; 2015 Sep; 14(9):2023-34. PubMed ID: 26285778
[TBL] [Abstract][Full Text] [Related]
24. Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives.
Norman MH; Liu L; Lee M; Xi N; Fellows I; D'Angelo ND; Dominguez C; Rex K; Bellon SF; Kim TS; Dussault I
J Med Chem; 2012 Mar; 55(5):1858-67. PubMed ID: 22320343
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
Cui JJ; McTigue M; Nambu M; Tran-Dubé M; Pairish M; Shen H; Jia L; Cheng H; Hoffman J; Le P; Jalaie M; Goetz GH; Ryan K; Grodsky N; Deng YL; Parker M; Timofeevski S; Murray BW; Yamazaki S; Aguirre S; Li Q; Zou H; Christensen J
J Med Chem; 2012 Sep; 55(18):8091-109. PubMed ID: 22924734
[TBL] [Abstract][Full Text] [Related]
26. Guilty as charged: B-RAF is a human oncogene.
Garnett MJ; Marais R
Cancer Cell; 2004 Oct; 6(4):313-9. PubMed ID: 15488754
[TBL] [Abstract][Full Text] [Related]
27. Regulation of MET kinase inhibitor resistance by copy number of MET in gastric carcinoma cells.
Funakoshi Y; Mukohara T; Ekyalongo RC; Tomioka H; Kataoka Y; Shimono Y; Chayahara N; Toyoda M; Kiyota N; Fujiwara Y; Minami H
Oncol Res; 2013; 21(6):287-93. PubMed ID: 25198658
[TBL] [Abstract][Full Text] [Related]
28. Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in
Sase H; Nakanishi Y; Aida S; Horiguchi-Takei K; Akiyama N; Fujii T; Sakata K; Mio T; Aoki M; Ishii N
Mol Cancer Ther; 2018 Oct; 17(10):2217-2225. PubMed ID: 30045926
[No Abstract] [Full Text] [Related]
29. Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay.
Liang Z; Ding X; Ai J; Kong X; Chen L; Chen L; Luo C; Geng M; Liu H; Chen K; Jiang H
Org Biomol Chem; 2012 Jan; 10(2):421-30. PubMed ID: 22108637
[TBL] [Abstract][Full Text] [Related]
30. MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential.
Jeuken JW; Wesseling P
J Pathol; 2010 Dec; 222(4):324-8. PubMed ID: 20976706
[TBL] [Abstract][Full Text] [Related]
31. TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells.
Hekmat O; Munk S; Fogh L; Yadav R; Francavilla C; Horn H; Würtz SØ; Schrohl AS; Damsgaard B; Rømer MU; Belling KC; Jensen NF; Gromova I; Bekker-Jensen DB; Moreira JM; Jensen LJ; Gupta R; Lademann U; Brünner N; Olsen JV; Stenvang J
J Proteome Res; 2013 Sep; 12(9):4136-51. PubMed ID: 23909892
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes.
Chmielecki J; Hutchinson KE; Frampton GM; Chalmers ZR; Johnson A; Shi C; Elvin J; Ali SM; Ross JS; Basturk O; Balasubramanian S; Lipson D; Yelensky R; Pao W; Miller VA; Klimstra DS; Stephens PJ
Cancer Discov; 2014 Dec; 4(12):1398-405. PubMed ID: 25266736
[TBL] [Abstract][Full Text] [Related]
33. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.
Smolen GA; Sordella R; Muir B; Mohapatra G; Barmettler A; Archibald H; Kim WJ; Okimoto RA; Bell DW; Sgroi DC; Christensen JG; Settleman J; Haber DA
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2316-21. PubMed ID: 16461907
[TBL] [Abstract][Full Text] [Related]
34. Indazoles as potential c-Met inhibitors: design, synthesis and molecular docking studies.
Ye L; Ou X; Tian Y; Yu B; Luo Y; Feng B; Lin H; Zhang J; Wu S
Eur J Med Chem; 2013 Jul; 65():112-8. PubMed ID: 23702473
[TBL] [Abstract][Full Text] [Related]
35. Scaffold-based design of kinase inhibitors for cancer therapy.
Zhang C; Bollag G
Curr Opin Genet Dev; 2010 Feb; 20(1):79-86. PubMed ID: 19932020
[TBL] [Abstract][Full Text] [Related]
36. Structural optimization and biological screening of a steroidal scaffold possessing cucurbitacin-like functionalities as B-Raf inhibitors.
Ahmed MS; Kopel LC; Halaweish FT
ChemMedChem; 2014 Jul; 9(7):1361-7. PubMed ID: 24682977
[TBL] [Abstract][Full Text] [Related]
37. Phosphoproteomics for the discovery of kinases as cancer biomarkers and drug targets.
Yu LR; Issaq HJ; Veenstra TD
Proteomics Clin Appl; 2007 Sep; 1(9):1042-57. PubMed ID: 21136756
[TBL] [Abstract][Full Text] [Related]
38. c-Met kinase inhibitors: an update patent review (2014-2017).
Zhang QW; Ye ZD; Shi L
Expert Opin Ther Pat; 2019 Jan; 29(1):25-41. PubMed ID: 30474428
[TBL] [Abstract][Full Text] [Related]
39. Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: From oncogenic addiction to druggable targets.
Konstantakou EG; Velentzas AD; Anagnostopoulos AK; Litou ZI; Konstandi OA; Giannopoulou AF; Anastasiadou E; Voutsinas GE; Tsangaris GT; Stravopodis DJ
PLoS One; 2017; 12(2):e0171512. PubMed ID: 28158294
[TBL] [Abstract][Full Text] [Related]
40. A low-grade malignant soft tissue tumor with S100 and CD34 co-expression showing novel CDC42SE2-BRAF fusion with distinct features.
Sheng SJ; Li JM; Zou YF; Peng XJ; Wang QY; Fang HS; Li X; Ding Y; Fan QH; Zhang ZH; Wei YZ; Gong QX
Genes Chromosomes Cancer; 2020 Oct; 59(10):595-600. PubMed ID: 32447786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
